Global Thrombocythemia Market – Industry Trends and Forecast to 2029

Global Thrombocythemia Market, By Treatment (Anti-Platelet Treatment, Platelet-Lowering, Antineoplastic Agent, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Thrombocythemia Market Analysis and Size

The global thrombocythemia market is expected to witness significant growth during the forecast period. According tor the MPN Research Foundation, Essential Thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) typically characterized by an accumulation of  huge number of platelets in the blood. The diagnosis of this disease is based on blood tests such as genetic screening, complete blood count, blood smear investigation, and bone marrow testing. Few patients may not show symptoms but have a rising platelets count. In some patients, symptoms are not visible but have an increased platelet count. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global thrombocythemia market in the forecast period 2022-2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Thrombocythemia Market Scope and Segmentation

Market Definition

Thrombocythemia, also known as thrombocytosis, is a haematological bleeding disorder characterised by abnormally high blood platelet concentration. Platelet is the main component of blood that is responsible for the blood clotting. Increased count of platelet can lead to either too much clotting or insufficient clotting. This disease occurs because of mutation in JAK2, CALR genes. These mutations lead to abnormal hyperactive signalling of a pathway called JAK pathway. leading to thrombocythemia.  

Global Thrombocythemia Market Dynamics

Drivers

• Prevalence of Thrombocythemia

According to the reports, the total prevalent population of Thrombocythemia was found to be 232,688 in 2017. The estimated increasing prevalence of thrombocythemia in the United States was around 142,635 cases in 2017. The rate of incidence of thrombocythemia in women is 1.5 times higher than men. This boosts the market growth.

• Growing Drug Development Process

Various drugs are aiding in boosting the market growth. Drugs such as hydroxyurea, anagrelide and interferon alfa-2b are popular in the treatment. Plateletpheresis is used very rarely which means the removal of platelets. There are few asymptomatic patients need not require any treatment. A drug called IMG-7289 is under phase 2 clinical trial to treat thrombocythemia. Thrombocythemia affects about 1 to 24 per 1 million people globally.

Opportunities

• Rise in Elderly Population

According to research, elderly population is more prone to suffer from this disease. According to the Aging World reports from 2015, there were approximately 562 million people 65 and older worldwide, which increased the disease's incidence and fueled the growth of the thrombocytothemia market.

• Increasing Demand for Retail Pharmacies

The rise in the number of drugs for thrombocytothemia being delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Side Effects of Treatments

There are various side-effects associated with the treatment options of idiopathic thrombocytopenic purpura. Side effects such as fluid retention, heart problems, headaches, dizziness, nausea and diarrhea hamper the market growth. Additionally, Interferon alfa-2b (Intron A) or peginterferon alfa-2a (Pegasys) given in the form of injection, and may cause severe side effects than hydroxyurea or anagrelide does. Thus, this hampers the market growth.

• Increased Cost of Screening

The high cost associated with the diagnosis, mainly genetic screening is a significant setback for its market growth. Diagnosis involves tests such as complete blood count, blood smear investigation, genetic screening and bone marrow testing, which require huge expenditure. This hampers the market growth.

This global thrombocythemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global thrombocythemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Thrombocythemia Market

COVID-19 disease mainly affects the lungs, but it could cause complex multiorgan effects. Mnay earlier studies showed that thrombosis has been complicated with COVID-19 infection. Thrombocythemia could cause thrombosis complicated with COVID-19. The healthcare professionals should consider the possibility of thromboembolic events. Thrombocytopenia has been witnessed in patients hospitalized with COVID-19, and lower platelet counts are related with worse clinical outcomes. Thus, COVID-19 left a major impact on the global thrombocythemia market.

Global Thrombocythemia Market Scope

The global thrombocythemia market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Anti-Platelet Treatment
• Platelet-Lowering
• Antineoplastic Agent
• Others

Route of Administration

• Oral
• Injectable

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Thrombocythemia Market Regional Analysis/Insights

The global thrombocythemia market is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global thrombocythemia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global thrombocythemia market throughout the forecasted period due to high prevalence of bleeding disorders.

North America dominates the market due to the high demand for disease-specific treatment, the rise in adoption of newer technologies, the presence of refined healthcare infrastructure and increased patient awareness.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Thrombocythemia Market Share Analysis

The global thrombocythemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to global thrombocythemia market.

Key players operating in the global thrombocythemia market include:

• Pfizer Inc (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Mylan N.V. (U.S.)
• Fresenius Kabi AG (Germany)
• Hikma Pharmaceuticals PLC (Japan)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bristol Myers Squibb Company (U.S.)
• GSK Plc. (U.K)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd (India)
• Boehringer Ingelheim International Gmbh (Germany)
• Sanofi (France)
• Astrazeneca (U.K.)
• AbbVie Inc. (U.S.)